Logo image of BGXX

BRIGHT GREEN CORP (BGXX) Stock Fundamental Analysis

NASDAQ:BGXX - Nasdaq - US10920G1004 - Common Stock - Currency: USD

0.1481  -0.04 (-22.01%)

After market: 0.155 +0.01 (+4.66%)

Fundamental Rating

0

Taking everything into account, BGXX scores 0 out of 10 in our fundamental rating. BGXX was compared to 194 industry peers in the Pharmaceuticals industry. BGXX may be in some trouble as it scores bad on both profitability and health. BGXX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BGXX has reported negative net income.
BGXX had a negative operating cash flow in the past year.
In the past 5 years BGXX always reported negative net income.
In the past 5 years BGXX always reported negative operating cash flow.
BGXX Yearly Net Income VS EBIT VS OCF VS FCFBGXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

BGXX has a worse Return On Assets (-62.04%) than 70.26% of its industry peers.
BGXX has a Return On Equity (-100.53%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.04%
ROE -100.53%
ROIC N/A
ROA(3y)-75.05%
ROA(5y)-54.76%
ROE(3y)-129.62%
ROE(5y)-88.27%
ROIC(3y)N/A
ROIC(5y)N/A
BGXX Yearly ROA, ROE, ROICBGXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BGXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGXX Yearly Profit, Operating, Gross MarginsBGXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, BGXX has more shares outstanding
The debt/assets ratio for BGXX has been reduced compared to a year ago.
BGXX Yearly Shares OutstandingBGXX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
BGXX Yearly Total Debt VS Total AssetsBGXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -3.41, we must say that BGXX is in the distress zone and has some risk of bankruptcy.
BGXX has a Altman-Z score of -3.41. This is comparable to the rest of the industry: BGXX outperforms 42.56% of its industry peers.
BGXX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
BGXX has a Debt to Equity ratio (0.05) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACCN/A
BGXX Yearly LT Debt VS Equity VS FCFBGXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 0.02 indicates that BGXX may have some problems paying its short term obligations.
BGXX has a worse Current ratio (0.02) than 99.49% of its industry peers.
A Quick Ratio of 0.02 indicates that BGXX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.02, BGXX is doing worse than 99.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
BGXX Yearly Current Assets VS Current LiabilitesBGXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.28% over the past year.
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGXX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGXX Price Earnings VS Forward Price EarningsBGXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGXX Per share dataBGXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BGXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIGHT GREEN CORP

NASDAQ:BGXX (9/18/2024, 8:00:00 PM)

After market: 0.155 +0.01 (+4.66%)

0.1481

-0.04 (-22.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)N/A N/A
Inst Owners0.07%
Inst Owner Change0%
Ins Owners65.87%
Ins Owner Change0%
Market Cap28.16M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.86
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.04%
ROE -100.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.05%
ROA(5y)-54.76%
ROE(3y)-129.62%
ROE(5y)-88.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -3.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)646.55%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.91%
OCF growth 3YN/A
OCF growth 5YN/A